Budesonide
Brand name: Budesonide Dr
Rank #327 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$33.1M
Total Cost
120,202
Total Claims
$33.1M
Total Cost
5,914
Prescribers
$275
Cost per Claim
9,869
Beneficiaries
155,905
30-Day Fills
$5,598
Avg Cost/Provider
20
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$33.1M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $33.1M total
Top Prescribers of Budesonide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Matthew Bristol | Podiatry | New York, NY | 158 | $677K |
| 2 | Wai Loon Bong | Physician Assistant | Flushing, NY | 65 | $279K |
| 3 | Jonathan Simhaee | Pain Management | New York, NY | 59 | $247K |
| 4 | Shumail Haque | Physical Medicine and Rehabilitation | Levittown, NY | 67 | $238K |
| 5 | Jorge Larranaga | Nephrology | Kissimmee, FL | 13 | $206K |
| 6 | Sergio Martinez | Pulmonary Disease | Jackson Heights, NY | 46 | $198K |
| 7 | Alexander Doan | Nephrology | San Jose, CA | 12 | $191K |
| 8 | Payam Shakouri | Nephrology | Poughkeepsie, NY | 12 | $191K |
| 9 | Nichole Wallace | Physician Assistant | Brooklyn, NY | 39 | $164K |
| 10 | Jaideep Chopra | Podiatry | Brooklyn, NY | 33 | $142K |
| 11 | Raymond Petit | Critical Care (Intensivists) | Attleboro, MA | 229 | $112K |
| 12 | Robert Adelson | Otolaryngology | Philadelphia, PA | 362 | $111K |
| 13 | Julia Muradov | Podiatry | Staten Island, NY | 75 | $86K |
| 14 | Asher Rudowsky | Podiatry | Brooklyn, NY | 80 | $77K |
| 15 | Kelly Baker-Neel | Nurse Practitioner | Pollok, TX | 196 | $70K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 324 | Tapentadol Hcl (Nucynta) | $33.6M | 29,886 |
| 325 | Dorzolamide Hcl/Timolol Maleat (Dorzolamide-Timolol) | $33.5M | 1,096,480 |
| 326 | Morphine Sulfate (Morphine Sulfate Er) | $33.2M | 1,023,056 |
| 327 | Budesonide (Budesonide Dr) | $33.1M | 120,202 |
| 328 | Mavacamten (Camzyos) | $32.8M | 3,969 |
| 329 | Empagliflozin/Linagliptin (Glyxambi) | $32.6M | 34,331 |
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology